STOCK TITAN

Veradermics (MANE) SEC Filings, Feb-Apr 2026

MANE NYSE

Veradermics (MANE) SEC filings document the formal record behind the company’s late-stage dermatology drug development business. As a clinical-stage biopharmaceutical company focused on VDPHL01 for pattern hair loss, its filings are especially useful for reviewing clinical disclosures, financing activity, equity structure, compensation plans, and quarterly operating updates.

Quarterly reports on Form 10-Q provide detail on items such as marketable securities, stock-based compensation, common and preferred stock matters, pre-funded warrants, and other financial statement notes. Annual reports on Form 10-K, when filed, provide a fuller business and risk-factor record. For Veradermics, these periodic reports are important because the company’s public materials focus on clinical development rather than sales of an approved commercial product.

Form 8-K filings have been used by Veradermics to report material events, including financial results, Regulation FD disclosures, clinical trial data releases, public offering activity, and private placement activity. S-1 registration statements provide information about registered securities, underwriting terms, IPO-related matters, preferred stock conversion, related-party disclosures, and beneficial ownership tables. Form 4 filings, when filed, show insider transactions involving officers, directors, or other reporting persons.

For MANE filing research, key documents include 10-Q quarterly reports, future 10-K annual reports, S-1 registration statements, 8-K material-event reports, and any Form 4 insider transaction reports. Together, these filings show how Veradermics funds development, structures equity, and reports progress for its investigational dermatology program.

Rhea-AI Summary

Veradermics is offering 3,843,790 shares of common stock at $100.00 per share to raise gross proceeds of $384,379,000. The company concurrently agreed to sell pre-funded warrants in a private placement (PIPE) for 300,000 shares at $99.99999 each to affiliates of Suvretta Capital; those pre-funded warrants are immediately exercisable, subject to ownership limits. Net proceeds from the offering and PIPE are estimated at approximately $388.8 million (or $443.0 million if the underwriters’ option is fully exercised), which the company intends to use for commercial launch activities, manufacturing expansion, clinical development and general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
prospectus
-
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
other
-
Rhea-AI Summary

Veradermics is registering 3,350,000 shares of common stock or pre-funded warrants in a primary offering, alongside a concurrent private placement (PIPE), with the aggregate securities issued across both remaining 3,350,000. The company develops VDPHL01, an extended‑release oral minoxidil candidate for pattern hair loss in men and women. A Phase 2/3 trial in 519 men met all primary and key secondary endpoints, with VDPHL01 achieving 30.3 and 33.0 non‑vellus hairs/cm² increases versus 7.3 for placebo and high rates of patient‑reported improvement. Treatment was generally well tolerated without treatment‑related serious cardiac events. Veradermics estimates net proceeds of about $212.9 million from the offering and PIPE, assuming a $67.84 share price, and reported preliminary cash, cash equivalents and marketable securities of approximately $390.8 million as of March 31, 2026. Together, this capital is expected to fund operations into 2030, including commercialization preparation for VDPHL01 if approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.00%
Tags
registration
Rhea-AI Summary

Veradermics, Incorporated reports a preliminary unaudited balance of cash, cash equivalents and marketable securities of about $390.8 million as of March 31, 2026.

The figure was prepared by management and is subject to the company’s normal financial closing procedures, so the final amount in the unaudited condensed consolidated financial statements for the three months ended March 31, 2026 may differ materially. The company notes that Deloitte & Touche LLP has not audited, reviewed, examined, compiled or applied agreed-upon procedures to this preliminary data and therefore does not provide any assurance on it.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.00%
Tags
current report
-
Rhea-AI Summary

Veradermics, Inc. reported positive topline results from its Phase 2/3 Study ‘302’ of oral VDPHL01 in 519 men with mild-to-moderate pattern hair loss. The trial met all primary and key secondary endpoints, with once-daily and twice-daily doses showing significantly greater hair growth than placebo.

At Month 6, non‑vellus target area hair count increased by 30.3 hairs/cm² with once-daily VDPHL01 and 33.0 hairs/cm² with twice-daily dosing, versus 7.3 hairs/cm² for placebo. Patient-reported ‘improved’ or ‘much improved’ outcomes reached 48.4% and 62.9% in the active arms compared with 13.4% on placebo.

Any improvement in hair coverage was reported by 79.3% and 86.0% of VDPHL01 patients versus 35.6% on placebo, and investigators graded 72.0% and 84.4% of active-arm patients as improved. VDPHL01 was generally well tolerated, with no treatment-related serious adverse events or cardiac adverse events of special interest and treatment-emergent adverse event rates similar to placebo.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.55%
Tags
current report
-
Rhea-AI Summary

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on treating pattern hair loss (PHL) in men and women. Its lead candidate, VDPHL01, is an extended‑release oral form of minoxidil designed to boost hair growth while limiting cardiac side effects.

The company is running three registration-directed, placebo-controlled trials: two in male PHL patients using an 8.5 mg dose and one in female patients using a 4.5 mg dose, with all male trials fully enrolled. Early Phase 2 data in men showed faster, more consistent and denser hair regrowth versus historical topical and immediate‑release oral minoxidil, with 90.5% of patients reporting improved hair coverage at four months and generally good tolerability.

Veradermics estimates the current U.S. PHL treatment market at about $9 billion annually and plans a cash-pay, multi‑channel commercial strategy centered on dermatologists, direct‑to‑consumer advertising, social media and telehealth. The company intends to seek U.S. approval for VDPHL01 through the 505(b)(2) pathway and holds patents expected to extend into at least 2043, but highlights substantial ongoing losses, dependence on VDPHL01’s success, the need for additional financing, competitive pressures and significant clinical, regulatory and commercialization risks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
annual report
Rhea-AI Summary

Veradermics, Inc. reported a larger net loss for the fourth quarter and full year 2025 as it accelerated late-stage development of its oral hair-loss candidate VDPHL01 and prepared to go public. Net loss was $21.8 million for the quarter and $70.0 million for 2025, compared with $5.7 million and $26.5 million in 2024.

Research and development spending more than doubled to $62.1 million in 2025, and general and administrative costs also rose as the company scaled its organization. Cash, cash equivalents and marketable securities were $141.9 million at December 31, 2025, before an upsized IPO in February 2026 that raised approximately $294.8 million in gross proceeds, which the company expects will fund operations into 2029, including multiple Phase 3 readouts and a potential launch of VDPHL01 if approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
current report
-
Rhea-AI Summary

Veradermics, Inc director John W. Childs, through the John W. Childs 2013 Revocable Trust, indirectly bought 294,117 shares of Common Stock at $17.00 per share in an open‑market purchase. This amended Form 4 corrects the earlier report by clarifying that the shares are held via the revocable trust rather than J.W. Childs Associates (FL), L.P.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
insider
-
Rhea-AI Summary

Veradermics, Incorporated disclosed that venture funds affiliated with Longitude Capital and managing members Patrick G. Enright and Juliet Tammenoms Bakker have filed a Schedule 13D reporting a significant stake in its common stock. The Reporting Persons beneficially own 4,653,873 shares of common stock, representing 12.5% of the outstanding shares based on 37,339,464 shares outstanding as of February 5, 2026.

Longitude Venture Partners V, L.P. holds 2,600,399 shares, and Longitude 103.8 East, L.P. holds 2,053,474 shares, with voting and dispositive power shared through their general partners. These positions arose from investments in Veradermics’ Series B and Series C preferred stock and additional common shares purchased at $17.00 per share in the initial public offering. The investors state they hold the shares for general investment purposes, may increase or decrease their holdings over time, and are subject to a 180‑day lock-up following the IPO underwriting agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
ownership
Rhea-AI Summary

Veradermics, Inc. received a new major shareholder disclosure from Viking Global–affiliated funds. The group reports beneficial ownership of 2,151,493 shares of Veradermics common stock, representing 5.8% of the outstanding shares following the company’s initial public offering.

The position is held through two main Cayman Islands limited partnerships: Viking Global Opportunities Illiquid Investments Sub-Master LP with 1,290,896 shares and Viking Global Opportunities Drawdown (Aggregator) LP with 860,597 shares. Various Delaware general partner and management entities, including Viking Global Investors LP and Viking Global Opportunities Parent GP LLC, are listed as having shared voting and dispositive power.

Individuals O. Andreas Halvorsen, David C. Ott and Rose S. Shabet are each reported as beneficial owners of the full 2,151,493 shares through their roles on Viking’s executive committee, with no direct share ownership. The filing certifies that the securities were not acquired to change or influence control of Veradermics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
ownership

FAQ

How many Veradermics (MANE) SEC filings are available on StockTitan?

StockTitan tracks 67 SEC filings for Veradermics (MANE), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Veradermics (MANE)?

The most recent SEC filing for Veradermics (MANE) was filed on November 13, 2026.